Vonoprazan‐Containing Triple Therapy Based on Clarithromycin Susceptibility May Be Definitive Treatment Strategy for Eradication of <i>Helicobacter pylori</i>
Based on CAM susceptibility, VPZ-based triple therapy, VAM, afforded a high eradication rate of CAM-resistant <i>H. pylori</i> strains; whereas VAC was not effective for the eradication. Additionally, drug sensitivity tests are recommended when VPZ-based triple therapy is administered.
Authors
- Sumire Mori
- Yuki Yamazaki
- Satoru Iwamoto
- Taro Ueo
- Hirokazu Okada (ORCID: https://orcid.org/0000-0002-4712-863X)
- Yoshiko Nakano (ORCID: https://orcid.org/0000-0001-5394-8194)
- Yuichi Yamaga
- Hiroaki Yaku
- Yoshiyuki Ota
- Koki Kurouchi
- Masaki Murata
- Shin'ichi Miyamoto
- Misae Ogaya
- Yoichi Asano
- Noriko Hayashi
Institutions
- Kyoto Medical Center (JP)
Publication Details
- Journal
- JGH Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/jgh3.70357
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00